Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia. Using time-lapse videos during in vitro fertilisation (IVF), and before embryo transfer, the technology can predict the likelihood of an embryo to lead to a viable pregnancy. The AI technology will support elective single embryo transfer and is anticipated to shorten the time to pregnancy by helping Fertility & IVF practitioners to rank the most viable embryos for selection and transfer.
The initial purchase price related to the transfer amounted to USD 6 million. In addition to the initial purchase price, additional purchase price of USD 2 million may be paid in relation to product development targets.
Vitrolife is the market leader of time-lapse systems for use in assisted reproduction, providing undisturbed culture and improved selection of embryos. Vitrolife is listed on NASDAQ Stockholm Large Cap list.
Lindahl’s team consisted of Olof Thorsell (partner in charge), Hermina Kelly and Victor Wodlén.
